All In Biotech

Drug Trial Radar · NCT03198507

ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator

A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection

Last checked: Nov 19, 2026Latest source record: Mar 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 455 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

455

Actual

Start

Jun 18, 2017

Primary completion

Oct 24, 2018

Study completion Dec 13, 2018

Sponsor

Lead sponsor
RedHill Biopharma LimitedIndustry
Sponsor type
Industry
First posted
Jun 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H. pylori infection in dyspeptic patients against an active comparator.

Conditions

  • Helicobacter Pylori Infection
  • Dyspepsia

Interventions

  • RHB-105Drug

    The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of: * Rifabutin 150 mg * Amoxicillin 3000 mg * Omeprazole 120 mg One 50mg Riboflavin tablet to be taken once daily to maintain the blind.

  • Active ComparatorDrug

    The intended dose of the Active Comparator (250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of: * Amoxicillin 3000 mg * Omeprazole 120 mg One 50mg Riboflavin tablet to be taken once daily to maintain the blind.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Eradication of H. PyloriTime frame: 43-71 days after initiation of treatment

Locations

55 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Dothan, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    North Little Rock, Arkansas

  • Research Site

    Anaheim, California

  • Research Site

    Chula Vista, California

  • Research Site

    Lomita, California

  • Research site

    San Carlos, California

  • Research Site

    Bristol, Connecticut

  • Research Site

    Aventura, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Coral Springs, Florida

  • Research Site

    Homestead, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Lauderdale Lakes, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Orange City, Florida

  • Research Site

    Palm Harbor, Florida

  • Research Site

    Athens, Georgia

  • Research Site

    Macon, Georgia

  • Research Site

    Marietta, Georgia

  • Research Site

    Elwood, Indiana

  • Research Site

    Metairie, Louisiana

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Baltimore, Maryland

  • Research Site

    Chevy Chase, Maryland

  • Research Site

    Brockton, Massachusetts

  • Research Site

    Chesterfield, Missouri

  • Research Site

    Wyoming, Missouri

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Great Neck, New York

  • Research Site

    Concord, North Carolina

  • Research Site

    Davidson, North Carolina

  • Research Site

    Fayetteville, North Carolina

  • Research Site

    Greenville, North Carolina

  • Research Site

    Tulsa, Oklahoma

  • Research Site

    Greenville, South Carolina

  • Research Site

    Sioux Falls, South Dakota

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.